A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Author(s): Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS

Department of Neuroscience and Behavior, Faculty of Medicine, University of São Paulo and National Institute for Translational Medicine, Ribeirão Preto, SP-Brazil

Subject: Schizophrenia View the study

Abstract:

Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ(9)- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal models and in healthy volunteers.

Source: Current Pharmaceutical Design
Share Tweet

More medical studies related to Schizophrenia:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

https://www.gefest-sv.kiev.ua/

банк фотографий

ry-diplomer.com